ClinicalTrials.gg
CompletedNCT01632241EMBRACEUpdated Sep 8, 2021Results posted

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

A Phase 4 interventional study of Placebo plus standard therapy and Belimumab 10 mg/kg plus standard therapy in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 96 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-08.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
7th of 36
503 · median 81
Started
2013
with 1 other
Phase 4
10 of 36
2 open now
Registered
15th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 10 in phase 4, and was the 15th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).

Read the detailed description

Study participants receive stable standard therapy for lupus in addition to receiving either placebo (no active medicine) or belimumab. The controlled period of the study is 52 weeks. The random assignment in this study is "2 to 1" which means that for every 3 participants, 2 will receive belimumab and 1 will receive placebo. Participants who successfully complete the 52-week study may enter into a 6-month open-label extension. All participants in the open-label extension receive belimumab plus standard therapy.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • African Continental Ancestry Group
  • Autoimmune Disease
  • Antibodies
  • Minority Groups
  • Black Race
  • African Americans
  • SLE
  • Belimumab
  • Lupus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Self-identified black race.
  • Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) criteria
  • Have active SLE disease defined as a SELENA SLEDAI score >= 8 at screening
  • Have 2 unequivocally positive autoantibody test results defined as a positive antinuclear antibody (ANA) test [i.e., titer >= 1:80 by human epithelial cell line 2 (HEp-2) immunofluorescence assay (IFA) and/or positive enzyme immunoassay (EIA)] and/or a positive anti- double stranded deoxyribonucleic acid (dsDNA) (>= 30 international units [IU]/milliliter [mL]) serum antibody test as follows:

    • From 2 independent time points within the study screening period. Screening results must be based on the study's central laboratory results, OR
    • One positive historical test result and 1 positive test result during the screening period.

Historical documentation of a positive ANA test (e.g., HEp-2 IFA or EIA) or anti-dsDNA (eg, anti-dsDNA by any validated commercial assay) must include the date and type of the test, the name of the testing laboratory, numerical reference range, and a key that explains values provided as positive versus negative OR negative, equivocal/borderline positive). Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted.

  • On a stable SLE treatment regimen consisting of any of the following medications (alone or in combination) for a period of at least 30 days prior to Day 0 (i.e., day of 1st dose of study agent):

    • (prednisone or prednisone equivalent, up to 40 mg/day): For subjects on SLE combination therapy, their stable steroid dose must be fixed within the range of 0 to 40 mg/day (prednisone or prednisone equivalent). For subjects whose only SLE treatment is steroids, their stable steroid dose must be fixed within the range of 7.5 to 40 mg/day (prednisone or prednisone equivalent). For those subjects on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose.
    • Other or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g., tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine, mizoribine, or thalidomide.
    • Anti-malarials (e.g., hydroxychloroquine, chloroquine, quinacrine).
    • Non-steroidal anti-inflammatory drugs (NSAIDs).

Note:

  • Pre-existing SLE medications must be stable for at least 30 days prior to Day 0.
  • Corticosteroids may be added as new medication or their doses adjusted only up to 30 days prior to Day 0.
  • New SLE therapy other than corticosteroids must not be added within 60 days of Day 0.
  • A female subject is eligible to enter the study if she is:

    • Not pregnant or nursing;
    • Of non- defined as: pre-menopausal females with a documented tubal ligation, hysterectomy, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, or documented bilateral oophorectomy, OR defined as 12 months of spontaneous amenorrhea with an appropriate clinical profile [e.g., > 45 years, in the absence of hormone replacement therapy or other cause for amenorrhea]; in questionable cases obtain a blood sample for follicle stimulating hormone (FSH) and estradiol simultaneously to confirm. Diagnostic levels for FSH and estradiol vary by specific laboratories/assays;
    • OR is of child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening and urine hCG test prior to dosing AND agrees to use one of the methods for 2 weeks prior to the day of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 16 weeks following the last dose of study agent.
    • OR has only same-sex partners, when this is her preferred and usual lifestyle.
    • Have the ability to understand the requirements of the study, provide written (including consent for the use and disclosure of research-related health information), and comply with the study protocol procedures (including required study visits).

Exclusion criteria

Exclusion criteria:

  • Have received treatment with anti-B lymphocyte stimulator (BLyS) [belimumab] at any time.
  • Have received any of the following within 364 days of Day 0:

    • Abatacept
    • Other B cell targeted therapy (e.g., rituximab, other anti-cluster of differentiation [CD] 20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], BLyS-receptor fusion protein [BR3], TACI-Fc, or anti-B-cell activating factor [BAFF] (LY2127399).
    • A biologic agent other than B cell targeted therapy (e.g., abetimus sodium, anti-0L antibody [BG9588/IDEC-131]).
  • Have required 3 or more courses of systemic for concomitant conditions (e.g., asthma, atopic dermatitis) within 364 days of Day 0. (Topical or inhaled steroids are permitted.)
  • Have received any of the following within 90 days of Day 0:

    • Anti-tumor necrosis factor (TNF) therapy (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab).
    • Intravenous (IV) cyclophosphamide
    • Interleukin-1 receptor antagonist (anakinra).
    • Intravenous immunoglobulin (IVIG).
    • High dose prednisone or equivalent (> 100 mg/day).
    • Plasmapheresis.
  • Have received any of the following within 60 days of Day 0:

    • A non-biologic investigational agent.
    • Any new /immunomodulatory agent, anti-malarial, or NSAID Note: New inhaled and topical steroids and new topical immunosuppressive agents (e.g., eye drops, topical creams) are allowed. Any NSAID use for \< 1 week is allowed.
    • Any steroid injection (e.g., intramuscular, intraarticular, or intravenous).
  • Have received any of the following within 30 days of Day 0:

    • A .
    • A change in dose of a corticosteroid, other immunosuppressive/immunomodulatory agent, anti-malarial, or NSAID
  • Have severe lupus kidney disease (defined by proteinuria > 6 grams/24 hour or equivalent using spot urine protein to creatinine ratio, or serum creatinine > 2.5 mg/deciliter [dL]), or have severe active nephritis requiring acute therapy not permitted by protocol (e.g., IV cyclophosphamide within 90 days of Day 0), or have required hemodialysis or high-dose prednisone (> 100 mg/day) within 90 days of Day 0.
  • Have severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis, or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 0.
  • Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, , or infectious diseases) which, in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk.
  • Have a planned surgical procedure or a history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the principal investigator, makes the subject unsuitable for the study.
  • Have a history of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
  • Have required management of acute or chronic infections, as follows:

    • Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, and atypical mycobacteria).
    • Hospitalization for treatment of infection within 60 days of Day 0.
    • Use of parenteral (IV or intramuscular [IM]) antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within 60 days of Day 0.
  • Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation of type 4 or 5 on the screening Columbia-Suicide Severity Rating Scale (C-SSRS) in the last 2 months or who, in the investigator's opinion, pose a significant suicide risk.
  • Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 0.
  • Have a historically positive test or test positive at screening for (HIV) antibody, surface antigen (HBsAg), hepatitis B core antibody, or antibody.
  • Have an immunoglobulin (Ig)A deficiency (IgA level \< 10 mg/dL).
  • Have a grade 3 or greater laboratory abnormality based on the adverse event
  • Severity grading tables except for the following that are allowed:

    • Stable grade 3 (PT) secondary to anticoagulant, e.g., warfarin, treatment.
    • Stable grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.
    • Stable grade 3/4 proteinuria (\<=6 grams/24 hour equivalent by spot urine protein to creatinine ratio allowed).
    • Stable grade 3 hypoalbuminemia due to lupus nephritis, and not related to liver disease or malnutrition.
    • Stable grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If present, any abnormalities in (ALT) and/or aspartate transaminase (AST) must be \<=grade 2.
    • Stable grade 3 reduction due to lupus.
    • Stable grade 3 neutropenia or stable grade 3 white blood cell count.
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
503 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus standard therapy

    Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.

    Biological: Placebo plus standard therapy · Drug: Standard therapy

  • Experimental
    Belimumab 10 mg/kg plus standard therapy

    Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.

    Biological: Belimumab 10 mg/kg plus standard therapy · Drug: Standard therapy

Interventions

  • BiologicalPlacebo plus standard therapy

    Placebo plus standard therapy

  • BiologicalBelimumab 10 mg/kg plus standard therapy

    Drug page: Belimumab

    Belimumab 10mg/kg plus standard therapy

  • DrugStandard therapy

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]

    SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in Lupus National Assessment(SELENA)SLEDAI\[SS\] score (with modified SLEDAI-2K scoring for proteinuria \[PU\]), no worsening (increase of \<0.30 points from Baseline) in Physician's Global Assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics(BILAG)A organ domain score \[ODS\] or 2 new BILAG B ODS compared with Baseline. Drop-outs and treatment failures were set to non-responders. Analysis performed using a logistic regression model for comparison between belimumab and placebo with covariates treatment group, Baseline SS score (with modified SLEDAI-2K scoring for PU) (\<=9 versus \[vs.\] \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (United States \[US\]/Canada vs. Rest of World). The Modified Intention-To-Treat (mITT) population comprised of safety population excluding participants who had any assessment at 3 sites (202196, 202513 or 107286).

    Time frame: Week 52

  2. Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase

    SRI response is defined as \>=4 point reduction, from OL Baseline in SS score (with the modified SLEDAI-2K scoring for PU), no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the OL phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the OL phase, Baseline was defined as Day 1 of the double-blind phase.

    Time frame: Week 24 of OL phase (Week 76)

  3. Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  4. Number of Participants With Severe AEs [OL Phase]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  5. Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  6. Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]

    Blood samples were collected for the assessment of hematology parameters. The parameters assessed were activated partial thromboplastin time (APTT), hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to Division of Microbiology and Infectious Diseases (DMID \[Modified from DMID Adult Toxicity Tables, 2001\]) AE Severity Grading. Number of participants with worst toxicity Grade 3 or 4 for hematology parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  7. Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]

    Blood samples were collected for the assessment of liver function and other chemistry parameters. The parameters assessed were alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), bilirubin, albumin, creatinine, hyperglycemia, hypoglycemia and urate. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for liver function and other chemistry parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  8. Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]

    Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

  9. Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]

    Serum samples were obtained for the measurement of immunoglobulin G. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 of immunoglobulin G have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

    Time frame: Week 52 to Week 84

Secondary outcomes

  1. Percentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase]

    SRI is defined as \>=4 point reduction, from Baseline in SS score, no worsening (increase of \<0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Drop-outs and Treatment failures were set to non-responders. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SS score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).

    Time frame: Week 52

  2. Percentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase

    SRI response is defined as \>=4 point reduction, from OL Baseline in SS scoring for PU, no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase.

    Time frame: Week 24 of OL phase (Week 76)

  3. Time to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase]

    Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes severe flares (SF) that were triggered only by an increase in SS score to \>12 (this may only represent a modest increase in disease activity). Treatment failures were imputed as SF. For participants who died, data were censored at date of death if no SF occurred before death. Only post-Baseline SF were considered. Analysis was performed using Cox proportional hazards model for the comparison between belimumab and placebo adjusting for Baseline SS-S2K score (\<=9 vs. \>=10), baseline complement levels (at least 1 C3/C4 low vs. no C3/C4 low), and region (US/Canada vs. Rest of World). Median and inter-Quartile range (1st and 3rd Quartiles) have been presented.

    Time frame: Up to 52 Weeks

  4. Time to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase]

    Time to first severe SLE flare is defined as the number of days from OL treatment start date until the participant met an event (event date - OL treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes SF that were triggered only by an increase in SS score to \>12. For participants who died, data were censored at date of death if no SF occurred before death. Only post first OL treatment SF were considered. Median and inter-Quartile range (25th and 75th percentile) have been presented.

    Time frame: Up to Week 24 of OL Phase (Week 76)

  5. Percent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase]

    Average (avg.) daily prednisone (PRED.) dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both Systemic Lupus Erythema (SLE) and non-SLE reasons. A responder was defined as having a PRED. reduction \[REDN.\] by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. Drop-outs and Treatment failures were imputed as having no REDN. in PRED. (if Baseline PRED. \>7.5 mg/day). At Baseline, the avg. daily prednisone dose \[PD\] was the sum of all PDs over 7 consecutive days \[excluding Day 0\], divided (DIV.) by 7. For analysis, the avg. PD was the total PD during Weeks 40 through 52 DIV. by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline PD, Baseline SS-S2K score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).

    Time frame: Baseline and Week 40 through Week 52

  6. Percent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase)

    Average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as a participant who decreased their daily prednisone dose to \<=7.5 mg/day from an OL Baseline dose \>7.5 mg/day. The OL Baseline was defined as the last available value prior to the initiation of treatment with belimumab. The average daily prednisone dose was the sum of all PDs over 7 consecutive days including OL Week 28 divided by 7. Only those participants with data available at the specified data points were analyzed.

    Time frame: OL Baseline and Week 28 of OL Phase (Week 80)

  7. Number of Participants With nSAEs and SAEs [DB Phase]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Safety population was defined as all participants who were randomized and treated with at least one dose of study treatment. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented.

    Time frame: Up to 52 Weeks

  8. Number of Participants With Severe AEs [DB Phase]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented.

    Time frame: Up to 52 Weeks

  9. Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented.

    Time frame: Up to 52 Weeks

  10. Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [DB Phase]

    Blood samples were collected for the assessment of hematology parameters up to 52 Weeks. The parameters assessed were APTT, hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for hematology parameters have been presented.

    Time frame: Up to 52 weeks

  11. Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [DB Phase]

    Blood samples were collected for the assessment of liver function and other chemistry parameters up to 52 Weeks. The parameters assessed were ALT, AST, GGT, albumin, hyperglycemia and hypoglycemia. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity Grade of 3 or 4 for other chemistry parameters have been presented.

    Time frame: Up to 52 weeks

  12. Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [DB Phase]

    Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 52 Weeks. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented.

    Time frame: Up to 52 weeks

07

Results

Posted Jul 5, 2019

Participant flow

This study evaluated the efficacy and safety of belimumab compared with placebo in adult participants with Systemic Lupus Erythematosus (SLE). This was a multicenter study conducted at United States (88 centers), United Kingdom (6), South Africa (5), France (4), Columbia (6) and Brazil (18).

Double-blinded (Up to Week 52)
Participant flow — Double-blinded (Up to Week 52)
MilestonePlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
Started165331
Completed121252
Not completed4479
Withdrew: Site closed35
Withdrew: Protocol violation26
Withdrew: Lost to follow-up18
Withdrew: Physician decision912
Withdrew: Lack of efficacy915
Withdrew: Withdrawal by subject1014
Withdrew: Adverse event1019
Open-label (Week 52 to Week 76)
Participant flow — Open-label (Week 52 to Week 76)
MilestonePlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
Started117242
Completed107220
Not completed1022
Withdrew: Withdrawal by subject52
Withdrew: Physician decision14
Withdrew: Lost to follow-up14
Withdrew: Site closed28
Withdrew: Protocol violation02
Withdrew: Lack of efficacy02
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]

SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in Lupus National Assessment(SELENA)SLEDAI\[SS\] score (with modified SLEDAI-2K scoring for proteinuria \[PU\]), no worsening (increase of \<0.30 points from Baseline) in Physician's Global Assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics(BILAG)A organ domain score \[ODS\] or 2 new BILAG B ODS compared with Baseline. Drop-outs and treatment failures were set to non-responders. Analysis performed using a logistic regression model for comparison between belimumab and placebo with covariates treatment group, Baseline SS score (with modified SLEDAI-2K scoring for PU) (\<=9 versus \[vs.\] \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (United States \[US\]/Canada vs. Rest of World). The Modified Intention-To-Treat (mITT) population comprised of safety population excluding participants who had any assessment at 3 sites (202196, 202513 or 107286).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]
Percentage of participantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]41.648.7
Statistical analysis
  • Placebo (DB Phase) vs Belimumab 10 mg/kg (DB Phase) · Regression, Logistic · p = 0.1068 · Odds ratio (or): 1.40 · 95% CI 0.93 to 2.11
PrimaryPercentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase

SRI response is defined as \>=4 point reduction, from OL Baseline in SS score (with the modified SLEDAI-2K scoring for PU), no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the OL phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the OL phase, Baseline was defined as Day 1 of the double-blind phase.

Time frame:
Week 24 of OL phase (Week 76)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase
Percentage of participantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase18.873.6
PrimaryNumber of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
nSAEs2349
SAEs613
PrimaryNumber of Participants With Severe AEs [OL Phase]

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Severe AEs [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Number of Participants With Severe AEs [OL Phase]109
PrimaryNumber of Participants With AEs Leading to Treatment Discontinuation [OL Phase]

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]10
PrimaryNumber of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]

Blood samples were collected for the assessment of hematology parameters. The parameters assessed were activated partial thromboplastin time (APTT), hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to Division of Microbiology and Infectious Diseases (DMID \[Modified from DMID Adult Toxicity Tables, 2001\]) AE Severity Grading. Number of participants with worst toxicity Grade 3 or 4 for hematology parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
APTT, Grade 3, n=93,20301
APTT, Grade 4, n=93,20300
Hemoglobin, Grade 3, n=115,23546
Hemoglobin, Grade 4, n=115,23500
Leukocytes, Grade 3, n=114,23506
Leukocytes, Grade 4, n=114,23500
Neutrophils, Grade 3, n=114,23426
Neutrophils, Grade 4, n=114,23401
Platelets, Grade 3, n=115,23500
Platelets, Grade 4, n=115,23500
Prothrombin time, Grade 3, n=93, 20432
Prothrombin time, Grade 4, n=93, 20413
PrimaryNumber of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]

Blood samples were collected for the assessment of liver function and other chemistry parameters. The parameters assessed were alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), bilirubin, albumin, creatinine, hyperglycemia, hypoglycemia and urate. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for liver function and other chemistry parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
ALP, Grade 300
ALP, Grade 400
ALT, Grade 300
ALT, Grade 400
AST, Grade 300
AST, Grade 400
Bilirubin, Grade 300
Bilirubin, Grade 400
GGT, Grade 301
GGT, Grade 400
Albumin, Grade 302
Albumin, Grade 410
Creatinine, Grade 300
Creatinine, Grade 400
Hypoglycemia, Grade 300
Hypoglycemia, Grade 400
Hyperglycemia, Grade 314
Hyperglycemia, Grade 400
Urate, Grade 300
Urate, Grade 400
PrimaryNumber of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]

Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Protein, Grade 3, n=115, 23400
Protein, Grade 4, n=115,23400
Protein/Creatinine, Grade 3,n=112,22755
Protein/Creatinine, Grade 4, n=112,22730
PrimaryNumber of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]

Serum samples were obtained for the measurement of immunoglobulin G. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 of immunoglobulin G have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Time frame:
Week 52 to Week 84
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]
ParticipantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Grade 301
Grade 400
SecondaryPercentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase]

SRI is defined as \>=4 point reduction, from Baseline in SS score, no worsening (increase of \<0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Drop-outs and Treatment failures were set to non-responders. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SS score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase]
Percentage of participantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Percentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase]41.649.0
Statistical analysis
  • Placebo (DB Phase) vs Belimumab 10 mg/kg (DB Phase) · Regression, Logistic · p = 0.0937 (Nominal p-value due to step-down sequential testing procedure.) · Odds ratio (or): 1.42 · 95% CI 0.94 to 2.15
SecondaryPercentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase

SRI response is defined as \>=4 point reduction, from OL Baseline in SS scoring for PU, no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase.

Time frame:
Week 24 of OL phase (Week 76)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase
Percentage of participantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Percentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase19.473.1
SecondaryTime to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase]

Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes severe flares (SF) that were triggered only by an increase in SS score to \>12 (this may only represent a modest increase in disease activity). Treatment failures were imputed as SF. For participants who died, data were censored at date of death if no SF occurred before death. Only post-Baseline SF were considered. Analysis was performed using Cox proportional hazards model for the comparison between belimumab and placebo adjusting for Baseline SS-S2K score (\<=9 vs. \>=10), baseline complement levels (at least 1 C3/C4 low vs. no C3/C4 low), and region (US/Canada vs. Rest of World). Median and inter-Quartile range (1st and 3rd Quartiles) have been presented.

Time frame:
Up to 52 Weeks
Reported as:
Median · Days
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase]
DaysPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase]NA (346 to NA)NA (NA to NA)
Statistical analysis
  • Placebo (DB Phase) vs Belimumab 10 mg/kg (DB Phase) · Cox proportional hazards model · p = 0.2264 (Nominal p-value due to step-down sequential testing procedure.) · Hazard ratio (hr): 0.77 · 95% CI 0.51 to 1.17
SecondaryTime to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase]

Time to first severe SLE flare is defined as the number of days from OL treatment start date until the participant met an event (event date - OL treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes SF that were triggered only by an increase in SS score to \>12. For participants who died, data were censored at date of death if no SF occurred before death. Only post first OL treatment SF were considered. Median and inter-Quartile range (25th and 75th percentile) have been presented.

Time frame:
Up to Week 24 of OL Phase (Week 76)
Reported as:
Median · Days
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase]
DaysPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase]NA (NA to NA)232 (232 to NA)
SecondaryPercent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase]

Average (avg.) daily prednisone (PRED.) dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both Systemic Lupus Erythema (SLE) and non-SLE reasons. A responder was defined as having a PRED. reduction \[REDN.\] by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. Drop-outs and Treatment failures were imputed as having no REDN. in PRED. (if Baseline PRED. \>7.5 mg/day). At Baseline, the avg. daily prednisone dose \[PD\] was the sum of all PDs over 7 consecutive days \[excluding Day 0\], divided (DIV.) by 7. For analysis, the avg. PD was the total PD during Weeks 40 through 52 DIV. by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline PD, Baseline SS-S2K score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).

Time frame:
Baseline and Week 40 through Week 52
Reported as:
Number · Percentage of participants
Percent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase]
Percentage of participantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Percent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase]12.614.7
Statistical analysis
  • Placebo (DB Phase) vs Belimumab 10 mg/kg (DB Phase) · Regression, Logistic · p = 0.4996 (Nominal p-value due to step-down sequential testing procedure.) · Odds ratio (or): 1.30 · 95% CI 0.61 to 2.80
SecondaryPercent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase)

Average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as a participant who decreased their daily prednisone dose to \<=7.5 mg/day from an OL Baseline dose \>7.5 mg/day. The OL Baseline was defined as the last available value prior to the initiation of treatment with belimumab. The average daily prednisone dose was the sum of all PDs over 7 consecutive days including OL Week 28 divided by 7. Only those participants with data available at the specified data points were analyzed.

Time frame:
OL Baseline and Week 28 of OL Phase (Week 80)
Reported as:
Number · Percentage of participants
Percent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase)
Percentage of participantsPlacebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Percent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase)14.831.9
SecondaryNumber of Participants With nSAEs and SAEs [DB Phase]

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Safety population was defined as all participants who were randomized and treated with at least one dose of study treatment. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented.

Time frame:
Up to 52 Weeks
Reported as:
Count of participants · Participants
Number of Participants With nSAEs and SAEs [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
nSAE77196
SAE3136
SecondaryNumber of Participants With Severe AEs [DB Phase]

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented.

Time frame:
Up to 52 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Severe AEs [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Number of Participants With Severe AEs [DB Phase]3746
SecondaryNumber of Participants With AEs Leading to Treatment Discontinuation [DB Phase]

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented.

Time frame:
Up to 52 Weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase]1222
SecondaryNumber of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [DB Phase]

Blood samples were collected for the assessment of hematology parameters up to 52 Weeks. The parameters assessed were APTT, hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for hematology parameters have been presented.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
APTT, Grade 3, n=159,31803
APTT, Grade 4, n=159,31802
Hemoglobin, Grade 3, n=161,327515
Hemoglobin, Grade 4, n=161,32710
Leukocytes, Grade 3, n=161,327317
Leukocytes, Grade 4, n=161,32710
Neutrophils, Grade 3, n=161,327928
Neutrophils, Grade 4, n=161,32715
Platelets, Grade 3, n=161,32711
Platelets, Grade 4, n=161,32701
Prothrombin time, Grade 3, n=159, 318810
Prothrombin time, Grade 4, n=159,31826
SecondaryNumber of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [DB Phase]

Blood samples were collected for the assessment of liver function and other chemistry parameters up to 52 Weeks. The parameters assessed were ALT, AST, GGT, albumin, hyperglycemia and hypoglycemia. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity Grade of 3 or 4 for other chemistry parameters have been presented.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
ALT, Grade 302
AST, Grade 302
GGT, Grade 366
GGT, Grade 401
Albumin, Grade 353
Albumin, Grade 411
Hyperglycemia, Grade 347
Hyperglycemia, Grade 411
Hypoglycemia, Grade 304
Hypoglycemia, Grade 431
SecondaryNumber of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [DB Phase]

Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 52 Weeks. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [DB Phase]
ParticipantsPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)
Protein, Grade 3, n=161, 32401
Protein/creatinine, Grade 3,n=161,322825
Protein/creatinine, Grade 4, n=161,3221211

Adverse events

Collected over nSAEs and SAEs were collected from the start of study treatment up to Week 52 for Double Blind phase and from Week 52 to Week 84 for the Open Label phase. Participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (DB Phase)0/165 (0%)31/165 (18.8%)77/165 (46.7%)
Belimumab 10 mg/kg (DB Phase)2/331 (0.6%)36/331 (10.9%)196/331 (59.2%)
Placebo to Belimumab 10 mg/kg (OL Phase)0/117 (0%)6/117 (5.1%)23/117 (19.7%)
Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)0/242 (0%)13/242 (5.4%)49/242 (20.2%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)Placebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
PneumoniaInfections and infestations6/1652/3310/1172/242
PericarditisCardiac disorders3/1650/3310/1170/242
Lupus nephritisRenal and urinary disorders2/1651/3310/1170/242
Urinary tract infectionInfections and infestations2/1650/3310/1170/242
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1653/3310/1171/242
Acute myocardial infarctionCardiac disorders0/1651/3311/1170/242
AnaemiaBlood and lymphatic system disorders0/1651/3311/1170/242
Atrial fibrillationCardiac disorders1/1650/3311/1170/242
Cerebrovascular accidentNervous system disorders0/1651/3311/1170/242
SyncopeNervous system disorders0/1650/3311/1171/242
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo (DB Phase)Belimumab 10 mg/kg (DB Phase)Placebo to Belimumab 10 mg/kg (OL Phase)Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Upper respiratory tract infectionInfections and infestations14/16548/3314/11720/242
Urinary tract infectionInfections and infestations19/16543/3317/11713/242
HeadacheNervous system disorders18/16539/3310/1170/242
InfluenzaInfections and infestations17/16528/3317/11716/242
DiarrhoeaGastrointestinal disorders9/16531/3310/1170/242
NauseaGastrointestinal disorders15/16518/3310/1170/242
SinusitisInfections and infestations9/16526/3310/1170/242
InsomniaPsychiatric disorders10/16518/3310/1170/242
Back painMusculoskeletal and connective tissue disorders10/16516/3317/1173/242
VomitingGastrointestinal disorders7/16519/3310/1170/242

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kgTotal
Mean39.5 ± 12.0638.7 ± 11.0038.9 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kgTotal
Female158322480
Male7916
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kgTotal
Race — Black or African American165331496
08

Study locations

96 sites
  • GSK Investigational Site
    Birmingham, Alabama 35216, United States
  • GSK Investigational Site
    Covina, California 91723, United States
  • GSK Investigational Site
    La Palma, California 90623, United States
  • GSK Investigational Site
    Lakewood, California 90712, United States
  • GSK Investigational Site
    Los Alamitos, California 90720, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Murrieta, California 92563, United States
  • GSK Investigational Site
    Upland, California 91786, United States
  • GSK Investigational Site
    Bridgeport, Connecticut 06606, United States
  • GSK Investigational Site
    Washington, District of Columbia 20060, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    DeBary, Florida 32713, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33334, United States
  • GSK Investigational Site
    Longwood, Florida 32750, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Orlando, Florida 32806-6264, United States
  • GSK Investigational Site
    Plantation, Florida 33324, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Tampa, Florida 33603, United States
  • GSK Investigational Site
    Atlanta, Georgia 30303, United States
  • GSK Investigational Site
    Duluth, Georgia 30096, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Lansing, Michigan 48917, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89102, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89128, United States
  • GSK Investigational Site
    Clifton, New Jersey 07012, United States
  • GSK Investigational Site
    Brooklyn, New York 11201, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Brooklyn, New York 11215, United States
  • GSK Investigational Site
    Great Neck, New York 11021, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28210, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27617, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Columbus, Ohio 43203, United States
  • GSK Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Columbia, South Carolina 29204, United States
  • GSK Investigational Site
    Columbia, South Carolina 29229, United States
  • GSK Investigational Site
    Jackson, Tennessee 38305, United States
  • GSK Investigational Site
    Memphis, Tennessee 38119, United States
  • GSK Investigational Site
    Memphis, Tennessee 38163, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Dallas, Texas 75390-8550, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77034, United States
  • GSK Investigational Site
    The Woodlands, Texas 77382, United States
  • GSK Investigational Site
    Arlington, Virginia 22205-3606, United States
  • GSK Investigational Site
    Salvador, Bahía 40.050-410, Brazil
  • GSK Investigational Site
    Cuiaba, Mato Grosso 78048-902, Brazil
  • GSK Investigational Site
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • GSK Investigational Site
    Curitba, Paraná 80440-080, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-001, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-170, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610000, Brazil
  • GSK Investigational Site
    Campinas, São Paulo 13015-001, Brazil
  • GSK Investigational Site
    Santo André, São Paulo 09190-615, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais, 30150-221, Brazil
  • GSK Investigational Site
    Campo Grande, 79080-190, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 22411-001, Brazil
  • GSK Investigational Site
    São Paulo, 01323-020, Brazil
  • GSK Investigational Site
    São Paulo, 04032-060, Brazil
  • GSK Investigational Site
    São Paulo, 04039-901, Brazil
  • GSK Investigational Site
    São Paulo, 05652-900, Brazil
  • GSK Investigational Site
    Barranquilla, 080002, Colombia
  • GSK Investigational Site
    Bucaramanga, 680005, Colombia
  • GSK Investigational Site
    Cali, 760007, Colombia
  • GSK Investigational Site
    Medellin, 574, Colombia
  • GSK Investigational Site
    Fort De France, 97261, France
  • GSK Investigational Site
    Paris, 75014, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Durban, KwaZulu- Natal 4319, South Africa
  • GSK Investigational Site
    Diepkloof, 2013, South Africa
  • GSK Investigational Site
    Johannesburg, 2193, South Africa
  • GSK Investigational Site
    Panorama / Cape Town, 7500, South Africa
  • GSK Investigational Site
    Basildon, Essex SS165NL, United Kingdom
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
  • GSK Investigational Site
    London, SE1 7RT, United Kingdom
  • GSK Investigational Site
    London, WC1E 6JF, United Kingdom
  • GSK Investigational Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 Jan;74(1):112-123. doi: 10.1002/art.41900. Epub 2021 Dec 9. PubMed 34164944 ↗
  • Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. PubMed 34531304 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Jun 2018, 63 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2012
First posted
Jul 2, 2012
StartActual
Feb 19, 2013
Primary completionActual
Jun 18, 2018
CompletionActual
Jan 28, 2019
Results first posted
Jul 5, 2019
Last update
Sep 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01632241
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 2, 2012
Start date
Feb 19, 2013
Primary completion
Jun 18, 2018
Completion
Jan 28, 2019
Results posted
Jul 5, 2019
Last update
Sep 8, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion